1 domain / 2 areas / 1 specialization
Origin Therapeutics
Data updated
Origin Therapeutics Holdings Inc. is a publicly listed, actively managed investment issuer focused on equity investments in psychedelics-related companies. Public company materials place it in Vancouver, British Columbia, which strongly suggests a Canadian base.
The firm is positioned as a sector investor rather than an operating biotech, with a mandate to provide investors diversified exposure to private psychedelics companies. Its public materials and announcements show an emphasis on early-stage and growth-oriented psychedelic businesses, especially drug development.
Origin Therapeutics appears to function as a specialized capital provider in the psychedelic ecosystem, with portfolio updates centered on companies developing psilocybin-based therapies. That makes it relevant as a financing vehicle and visibility source for emerging psychedelic drug programs.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
Public Portfolio Examples
- Xpira PharmaceuticalsSep 22, 2022
- Clairvoyant TherapeuticsJul 7, 2022
Origin Therapeutics is an actively managed investment issuer that says it focuses on making equity investments in psychedelics-related companies, with an emphasis on private businesses and active involvement through management expertise, professional network, due diligence, and board or advisory participation. Public announcements indicate interest across psychedelic drug development and related sector verticals, and the company has highlighted portfolio exposure to clinical-stage programs such as psilocybin-based therapies.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Explicit Psychedelic Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Recorded Investments
Sep 22, 2022
Origin described Xpira as a portfolio company developing psychedelic medicines for eating disorders.
Origin Therapeutics’ Portfolio Company, Xpira Pharmaceuticals, Receives FDA Approval For Psilocybin Trial IND ApplicationJul 7, 2022
Origin announced Clairvoyant had been added to its portfolio, with a focus on psilocybin therapy for addiction.
Origin Therapeutics adds Clairvoyant Therapeutics to its PortfolioQuick Facts
- Founded
- 2021
- HQ
- Vancouver, British Columbia, Canada
- Website
- Visit